S100B and schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 67, Issue 2, 2013, Pages 67-75

  Yelmo Cruz, Silvia ^a   Morera Fumero, Armando L ^b,d   Abreu González, Pedro ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d NONE   (Spain)

Author keywords

astrocytes; first episode psychosis; neuroinflammation; S100B; schizophrenia

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTICOAGULANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PROTEIN S100B;

APOPTOSIS; ASTROCYTE; BODY MASS; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INSULIN RESISTANCE; MENTAL DISEASE; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGODENDROGLIA; PATHOGENESIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RHYTHM; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

BIOLOGICAL MARKERS; HUMANS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SCHIZOPHRENIA;

EID: 84874466207     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12024     Document Type: Review

References (75)

1. De Keyser J, Mostert JP, Koch MW,. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 2008; 267: 3-16.
2. Steiner J, Bogerts B, Schroeter ML, Bernstein HG,. S100B protein in neurodegenerative disorders. Clin. Chem. Lab. Med. 2011; 49: 409-424.
3. Schafer BW, Heizmann CW,. The S100 family of EF-hand calcium-binding proteins: Functions and pathology. Trends Biochem. Sci. 1996; 21: 134-140.
4. Moore BW,. A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun. 1965; 19: 739-744.
5. Gonçalves CA, Leite MC, Nardin P,. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin. Biochem. 2008; 41: 755-763.
6. Zhang XY, Xiu MH, Song C, et al. Increased serum S100B in never-medicated and medicated schizophrenic patients. J. Psychiatr. Res. 2010; 44: 1236-1240.
7. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V,. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004; 29: 1004-1011.
8. Rothermundt M, Falkai P, Ponath G, et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 2004; 9: 897-899.
9. Rothermundt M, Ponath G, Arolt V,. S100B in schizophrenic psychosis. Int. Rev. Neurobiol. 2004; 59: 445-470.
10. Donato R,. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 2001; 33: 637-668.
11. Van Eldik L, Wainwright M,. The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain. Restor. Neurol. Neurosci. 2003; 21: 97-108.
12. Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 2007; 8: 2-11.
13. Steiner J, Bernstein HG, Bielau H, et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. J. Psychiatr. Res. 2008; 42: 868-876.
14. Johnsson P, Backstrom M, Bergh C, Jonsson H, Luhrs C, Alling C,. Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality. Ann. Thorac. Surg. 2003; 75: 162-168.
15. Pham N, Fazio V, Cucullo L, et al. Extracranial sources of S100B do not affect serum levels. PLoS ONE 2010; 5: e12691.
16. Schroeter ML, Abdul-Khaliq H, Fruhauf S, et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res. 2003; 62: 231-236.
17. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D,. Peripheral markers of blood-brain barrier damage. Clin. Chim. Acta 2004; 342: 1-12.
18. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE,. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res. 2009; 167: 66-72.
19. Rothermundt M, Peters M, Prehn JH, Arolt V,. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 2003; 60: 614-632.
20. Topolovec-Vranic J, Pollmann-Mudryj MA, Ouchterlony D, et al. The value of serum biomarkers in prediction models of outcome after mild traumatic brain injury. J. Trauma 2011; 71: S478-S486.
21. Schroeter ML, Steiner J,. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol. Psychiatry 2009; 14: 235-237.
22. Sen J, Belli A,. S100B in neuropathologic states: The CRP of the brain? J. Neurosci. Res. 2007; 85: 1373-1380.
23. Portela LV, Tort AB, Schaf DV, et al. The serum S100B concentration is age dependent. Clin. Chem. 2002; 48: 950-952.
24. Gazzolo D, Vinesi P, Marinoni E, et al. S100B protein concentrations in cord blood: Correlations with gestational age in term and preterm deliveries. Clin. Chem. 2000; 46: 998-1000.
25. Beaudeux JL,. [S100B protein: A novel biomarker for the diagnosis of head injury]. Ann. Pharm. Fr. 2009; 67: 187-194.
26. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR,. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J. Neurotrauma 2005; 22: 645-655.
27. Brown AS,. Exposure to prenatal infection and risk of schizophrenia. Front. Psychiatry 2011; 2: 63-67.
28. Bechter K,. Updating the mild encephalitis hypothesis of schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2012; (Epub ahead of print).
29. Yolken RH, Torrey EF,. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008; 13: 470-479.
30. Katsel P, Davis KL, Li C, et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 2008; 33: 2993-3009.
31. Lara DR, Gama CS, Belmonte-de-Abreu P, et al. Increased serum S100B protein in schizophrenia: A study in medication-free patients. J. Psychiatr. Res. 2001; 35: 11-14.
32. van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D,. Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur. Neuropsychopharmacol. 2006; 16: 469-480.
33. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT,. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 2006; 77: 1284-1287.
34. Rothermundt M, Ahn JN, Jorgens S,. S100B in schizophrenia: An update. Gen. Physiol. Biophys. 2009; 28 Spec No Focus: F76-F81.
35. Miuller N, Schwarz MJ,. The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view. J. Neural Transm. Suppl. 2007; 72: 269-280.
36. Muller N, Schwarz M,. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006; 10: 131-148.
37. Tateishi N, Shimoda T, Yada N, Shinagawa R, Kagamiishi Y,. [S100B: Astrocyte specific protein]. Nihon Shinkei Seishin Yakurigaku Zasshi 2006; 26: 11-16.
38. Suchankova P, Klang J, Cavanna C, et al. Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? J. Psychiatry Neurosci. 2012; 37: 122-128.
39. Zhai J, Cheng L, Dong J, et al. S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr. Res. 2012; 134: 89-94.
40. Dagdan E, Morris DW, Campbell M, et al. Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011; 156B: 691-699.
41. Suchankova P, Baghaei F, Rosmond R, Holm G, Anckarsater H, Ekman A,. Genetic variability within the S100B gene influences the personality trait self-directedness. Psychoneuroendocrinology 2011; 36: 919-923.
42. Zhai J, Zhang Q, Cheng L, et al. Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. Behav. Brain Res. 2011; 217: 363-368.
43. Hohoff C, Ponath G, Freitag CM, et al. Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010; 153B: 291-297.
44. Roche S, Cassidy F, Zhao C, et al. Candidate gene analysis of 21q22: Support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007; 144B: 1094-1096.
45. Liu J, Shi Y, Tang J, et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem. Biophys. Res. Commun. 2005; 328: 335-341.
46. Falcone T, Fazio V, Lee C, et al. Serum S100B: A potential biomarker for suicidality in adolescents? PLoS ONE 2010; 5: e11089.
47. Park ES, Park CI, Choi KS, Choi IH, Shin JS,. Over-expression of S100B protein in children with cerebral palsy or delayed development. Brain Dev. 2004; 26: 190-196.
48. Ikeda Y, Umemura K,. [Analysis of reference values of serum S100B concentrations of Japanese adults]. Rinsho Byori 2005; 53: 395-399.
49. Qi LY, Xiu MH, Chen DC, et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci. Lett. 2009; 462: 113-117.
50. Schmitt A, Bertsch T, Henning U, et al. Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophr. Res. 2005; 80: 305-313.
51. Zhang XY, Xiu MH, Chen da C, et al. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. J. Psychiatr. Res. 2010; 44: 429-433.
52. Gattaz WF, Lara DR, Elkis H, et al. Decreased S100-beta protein in schizophrenia: Preliminary evidence. Schizophr. Res. 2000; 43: 91-95.
53. Steiner J, Schroeter ML, Schiltz K, et al. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 2010; 167: 1025-1031.
54. Tort AB, Dietrich MO, Gonçalves CA, Souza DO, Portela LV,. Influence of anticoagulants on the measurement of S100B protein in blood. Clin. Biochem. 2003; 36: 629-632.
55. Rothermundt M, Missler U, Arolt V, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 2001; 6: 445-449.
56. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E,. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 1164-1169.
57. Steiner J, Walter M, Wunderlich MT, et al. A new pathophysiological aspect of S100B in schizophrenia: Potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry 2009; 65: 1107-1110.
58. Pedersen A, Diedrich M, Kaestner F, et al. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2008; 32: 1789-1792.
59. Ling SH, Tang YL, Jiang F, et al. Plasma S-100B protein in Chinese patients with schizophrenia: Comparison with healthy controls and effect of antipsychotics treatment. J. Psychiatr. Res. 2007; 41: 36-42.
60. Woods SW,. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003; 64: 663-667.
61. Wiesmann M, Wandinger KP, Missler U, et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol. Psychiatry 1999; 45: 1508-1511.
62. Steiner J, Schiltz K, Walter M, et al. S100B serum levels are closely correlated with body mass index: An important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010; 35: 321-324.
63. Holtkamp K, Buhren K, Ponath G, et al. Serum levels of S100B are decreased in chronic starvation and normalize with weight gain. J. Neural Transm. 2008; 115: 937-940.
64. Chung YC, Park CH, Kwon HK, et al. Improved cognitive performance following supplementation with a mixed-grain diet in high school students: A randomized controlled trial. Nutrition 2012; 28: 165-172.
65. Suzuki F, Kato K,. Inhibition of adipose S-100 protein release by insulin. Biochim. Biophys. Acta 1985; 845: 311-316.
66. Gazzolo D, Florio P, Zullino E, et al. S100B protein increases in human blood and urine during stressful activity. Clin. Chem. Lab. Med. 2010; 48: 1363-1365.
67. Suzuki F, Kato K, Nakajima T,. Enhancement of adipose S-100 protein release by catecholamines. J. Biochem. 1983; 94: 1707-1710.
68. Netto CB, Conte S, Leite MC, et al. Serum S100B protein is increased in fasting rats. Arch. Med. Res. 2006; 37: 683-686.
69. Steiner J, Walter M, Guest P, et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol. Psychiatry 2010; 15: 3-4.
70. Diaz-Mesa E, Morera A, Abreu-Gonzalez P, et al. Circadian protein S100B rhythm in acute schizophrenic patients. Int. J. Neuropsychopharmacol. 2008; 11 (Suppl.1): 144 (abstract).
71. Monji A, Kato T, Kanba S,. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009; 63: 257-265.
72. Bianchi R, Adami C, Giambanco I, Donato R,. S100B binding to RAGE in microglia stimulates COX-2 expression. J. Leukoc. Biol. 2007; 81: 108-118.
73. Bianchi R, Kastrisianaki E, Giambanco I, Donato R,. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J. Biol. Chem. 2011; 286: 7214-7226.
74. Steiner J, Marquardt N, Pauls I, et al. Human CD8(+) T cells and NK cells express and secrete S100B upon stimulation. Brain Behav. Immun. 2011; 25: 1233-1241.
75. Steiner J, Westphal S, Schroeter ML, et al. Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav. Immun. 2012; 26: 564-567.